-
Je něco špatně v tomto záznamu ?
Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy
S. Kutilek,
Jazyk angličtina Země Írán
Typ dokumentu kazuistiky, časopisecké články
NLK
Directory of Open Access Journals
od 1956
Free Medical Journals
od 1956
ProQuest Central
od 2010-01-01
Open Access Digital Library
od 1956-01-01
Medline Complete (EBSCOhost)
od 2010-01-01 do 2018-01-31
Health & Medicine (ProQuest)
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1960
PubMed
29228533
Knihovny.cz E-zdroje
- MeSH
- denosumab terapeutické užití MeSH
- fraktury kostí farmakoterapie MeSH
- inhibitory kostní resorpce terapeutické užití MeSH
- injekce subkutánní MeSH
- kostní denzita účinky léků MeSH
- lidé MeSH
- mladiství MeSH
- osteoporóza farmakoterapie MeSH
- spinální svalová atrofie komplikace MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders. There are only very scarce data on denosumab treatment in children. 14-year-old boy with spinal muscular atrophy (SMA) and severe disuse osteoporosis (spinal bone mineral density L1-L4 BMD-6.2SD Z-score) and two prevalent fragility fractures was treated with denosumab. He received 60 mg subcutaneous injection at the baseline and seven months later. Six months after the initial injection there was a 19% increase in L1-L4 BMD. The injections were well tolerated without any adverse reactions. Calcemia remained stable (2.3-2.4 mmol/L). He was scheduled for the third denosumab injection six months later. Prior to this date, he acquired pneumonia and died due to respiratory failure, which is a frequent cause of death in patients with SMA. There was no relation to the denosumab treatment. In conclusion, one dose of denosumab significantly increased BMD in a child with severe osteoporosis.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024440
- 003
- CZ-PrNML
- 005
- 20181113094552.0
- 007
- ta
- 008
- 180709s2017 ir f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)29228533
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ir
- 100 1_
- $a Kutilek, Stepan $u Department of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic.
- 245 10
- $a Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy / $c S. Kutilek,
- 520 9_
- $a Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders. There are only very scarce data on denosumab treatment in children. 14-year-old boy with spinal muscular atrophy (SMA) and severe disuse osteoporosis (spinal bone mineral density L1-L4 BMD-6.2SD Z-score) and two prevalent fragility fractures was treated with denosumab. He received 60 mg subcutaneous injection at the baseline and seven months later. Six months after the initial injection there was a 19% increase in L1-L4 BMD. The injections were well tolerated without any adverse reactions. Calcemia remained stable (2.3-2.4 mmol/L). He was scheduled for the third denosumab injection six months later. Prior to this date, he acquired pneumonia and died due to respiratory failure, which is a frequent cause of death in patients with SMA. There was no relation to the denosumab treatment. In conclusion, one dose of denosumab significantly increased BMD in a child with severe osteoporosis.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a kostní denzita $x účinky léků $7 D015519
- 650 _2
- $a inhibitory kostní resorpce $x terapeutické užití $7 D050071
- 650 _2
- $a denosumab $x terapeutické užití $7 D000069448
- 650 _2
- $a fraktury kostí $x farmakoterapie $7 D050723
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a spinální svalová atrofie $x komplikace $7 D009134
- 650 _2
- $a osteoporóza $x farmakoterapie $7 D010024
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00000071 $t Acta medica Iranica $x 1735-9694 $g Roč. 55, č. 10 (2017), s. 658-660
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29228533 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20181113094637 $b ABA008
- 999 __
- $a ok $b bmc $g 1316571 $s 1021361
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 55 $c 10 $d 658-660 $i 1735-9694 $m Acta medica iranica $n Acta Med Iran $x MED00000071
- LZP __
- $a Pubmed-20180709